S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
MNPR · Monopar Therapeutics Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Monopar Therapeutics Inc (MNPR)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$72.21
-1.72
(-2.32%)
● At close: October 21 at 4:00:00 PM EDT
$72.35
+0.00
(+0.00%)
After-Hours:
4:00:11 PM EDT
DAY'S RANGE
$72.21
$71.31
$72.21
52-WEEK RANGE
$72.21
$50.07
$124.82
What's happening
- MNPR is down 2.32% today, trading at $72.21. — Live quote
- Volume today (2,797) is well below its 3-month average of 201,430. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 21 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.62 actual vs. $-0.63 estimated (+2.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 13
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MNPR
+13.68%
vs S&P 500
+0.90%
1-YEAR RETURN
MNPR
-3.78%
vs S&P 500
-18.35%
6-MONTH RETURN
MNPR
+28.65%
3-MONTH RETURN
MNPR
-34.64%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.62
Est. $-0.63
BEAT +2.1%
2026-04-26 (Q1 2026)
$-0.46
Est. $-0.85
BEAT +46.0%
2026-01-26 (Q4 2025)
$-0.64
Est. $-0.50
MISS -27.3%
2025-10-26 (Q3 2025)
$-0.48
Est. $-0.44
MISS -9.4%
Valuation Measures & Ratios
Enterprise Value4$446.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book74.74
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-13.08%
Return on Assets (ROA9)-12.79%
Avg Volume (3M)201,430
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,086,279
Change from Prior Settlement+28.67%
% of Float—
Days to Cover (Short Ratio)6.02
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -3.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MNPR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — | — | — | — |
| Operating income | -$6.6M | -$5.2M | -$4.1M | -$3.2M | -$3.2M | -$1.6M | -$1.8M | -$1.7M |
| Net income | -$5.3M | -$3.9M | -$3.4M | -$2.5M | -$2.6M | -$1.3M | -$1.7M | -$1.6M |
| EPS (basic) | $-0.62 | $-0.46 | $-0.48 | $-0.35 | $-0.38 | $-0.37 | $-0.49 | $-0.51 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $135.0M | $138.0M | $140.7M | $144.2M | $53.9M | $55.1M | $60.3M | $6.1M |
| Total liabilities | $4.1M | $2.6M | $2.9M | $2.6M | $1.7M | $1.5M | $5.3M | $1.1M |
| Stockholders' equity | $130.9M | $135.4M | $137.8M | $141.6M | $52.2M | $53.6M | $55.0M | $4.9M |
| Total current assets | $134.8M | $137.7M | $140.5M | $144.1M | $53.7M | $55.1M | $60.3M | $6.1M |
| Total current liabilities | $4.0M | $2.5M | $2.7M | $2.6M | $1.6M | — | $5.3M | — |
| Cash & equivalents | $52.8M | $52.5M | $61.8M | $127.7M | $39.5M | $39.7M | $45.8M | $6.0M |
| Other current assets | $464.7K | $250.9K | $63.7K | $414.8K | $497.3K | $523.6K | $78.9K | $49.6K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $6.7K | $6.7K | $6.7K | $6.7K | $6.1K | $6.1K | $6.1K | $3.5K |
| Retained earnings | -$98.7M | -$93.4M | -$89.5M | -$84.3M | -$80.9M | -$78.4M | -$75.8M | -$64.9M |
| Accumulated other comprehensive income (loss) | $91.3K | $98.5K | $131.4K | $11.7K | $77.6K | -$21.8K | $36.0K | -$11.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.2M | -$3.5M | -$3.4M | -$2.1M | -$1.1M | -$5.7M | -$2.0M | -$1.1M |
| Investing cash flow | $4.1M | -$5.6M | -$62.2M | -$2.1M | $1.2M | -$325.8K | -$14.3M | $985.7K |
| Financing cash flow | -$647.4K | -$200.2K | -$384.7K | $92.4M | -$316.8K | -$115.7K | $56.1M | -$16.5K |
| Share-based compensation | $1.4M | $1.7M | $1.1M | $1.1M | $1.3M | $1.4M | $278.6K | $199.1K |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | $0 | $35.0M | — | — | $0 | $0 |
| Tax withholding on stock comp | $655.0K | $200.2K | $298.1K | $381.6K | $321.6K | $131.1K | $66.9K | $16.5K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$16.7M | -$16.2M | -$8.8M | -$10.5M | -$9.1M |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | -$9.1M |
| EPS (basic) | $-1.85 | $-4.11 | $-3.04 | $-0.83 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $140.7M | $60.3M | $7.3M | $13.2M | $20.5M |
| Total liabilities | $2.9M | $5.3M | $1.8M | $3.1M | $1.6M |
| Stockholders' equity | $137.8M | $55.0M | $5.6M | $10.1M | $18.9M |
| Total current assets | $140.5M | $60.3M | $7.3M | $13.2M | $20.5M |
| Total current liabilities | $2.7M | $5.3M | $1.8M | $3.1M | $1.6M |
| Cash & equivalents | $61.8M | $45.8M | $7.3M | $8.2M | $20.3M |
| Other current assets | $63.7K | $78.9K | $66.4K | $46.0K | $217.7K |
| Other non-current assets | — | — | — | — | $0 |
| Common stock & paid-in capital | $6.7K | $6.1K | $3.0K | $12.9K | $12.6K |
| Retained earnings | -$89.5M | -$75.8M | -$60.2M | -$51.8M | -$41.3M |
| Accumulated other comprehensive income (loss) | $131.4K | $36.0K | -$14.1K | $8.9K | -$3.2K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.2M | -$6.4M | -$7.9M | -$7.2M | -$7.3M |
| Investing cash flow | -$63.5M | -$14.3M | $4.9M | -$4.9M | $0 |
| Financing cash flow | $91.6M | $59.3M | $2.0M | $32.9K | $10.9M |
| Share-based compensation | $4.8M | $1.1M | $1.9M | $1.6M | — |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Sales/maturities of investments | — | — | $0 | — | — |
| Share repurchases | $35.0M | $0 | — | — | — |
| Tax withholding on stock comp | $1.1M | $104.2K | $47.0K | $76.6K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MNPR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-28 to 2026-10-20
Recent transactions
- Insiders have net sold 44,689 shares over the last 182 days, across 0 purchases and 17 sales.
- Most recent: Robinson Chandler (Chief Executive Officer) — Tax withholding of 597 shares on 2026-10-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)44,689 sh(17 txns)
Net Shares-44,689
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Robinson Chandler | Chief Executive Officer | Tax withholding | 2026-10-20 | 597 |
| STARR CHRISTOPHER M | Director | Option exercise | 2026-10-01 | 8,400 |
| Cittadine Andrew | Chief Operating Officer | Option exercise | 2026-09-30 | 4,384 |
| Vu Quan Anh | Chief Financial Officer | Option exercise | 2026-09-30 | 614 |
| RIOUX PATRICE | Acting Chief Medical Officer | Option exercise | 2026-08-26 | 1,380 |
| Tsuchimoto Kim R | Director | Open market sale | 2026-08-26 | 485 |
| Anderson Raymond | Director | Open market sale | 2026-08-25 | 694 |
| KLAUSNER ARTHUR J | Director | Open market sale | 2025-12-18 | 4,660 |
| Hendricks Diane | 10% owner | Other acquisition/disposition | 2025-12-16 | 43,499 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-20 | Robinson Chandler | Chief Executive Officer | Tax withholding | 597 | $92.59 |
| 2026-10-01 | STARR CHRISTOPHER M | Director | Option exercise | 8,400 | $0.01 |
| 2026-10-01 | STARR CHRISTOPHER M | Director | Open market sale | 4,631 | $78.09 |
| 2026-10-01 | STARR CHRISTOPHER M | Director | Open market sale | 2,970 | $78.82 |
| 2026-10-01 | STARR CHRISTOPHER M | Director | Open market sale | 799 | $79.67 |
| 2026-09-30 | Cittadine Andrew | Chief Operating Officer | Option exercise | 4,384 | — |
| 2026-09-30 | Cittadine Andrew | Chief Operating Officer | Tax withholding | 1,944 | $79.67 |
| 2026-09-30 | Robinson Chandler | Chief Executive Officer | Option exercise | 9,801 | — |
| 2026-09-30 | Robinson Chandler | Chief Executive Officer | Tax withholding | 4,344 | $79.67 |
| 2026-09-30 | Vu Quan Anh | Chief Financial Officer | Option exercise | 614 | — |
| 2026-09-30 | Vu Quan Anh | Chief Financial Officer | Tax withholding | 180 | $79.67 |
| 2026-09-24 | Robinson Chandler | Chief Executive Officer | Option exercise | 14,056 | $30.00 |
| 2026-09-24 | Robinson Chandler | Chief Executive Officer | Option exercise | 15,000 | $14.00 |
| 2026-09-24 | Robinson Chandler | Chief Executive Officer | Open market sale | 10,450 | $87.15 |
| 2026-09-24 | Robinson Chandler | Chief Executive Officer | Open market sale | 9,638 | $87.96 |
| 2026-09-24 | Robinson Chandler | Chief Executive Officer | Open market sale | 8,368 | $88.97 |
| 2026-09-24 | Robinson Chandler | Chief Executive Officer | Open market sale | 600 | $89.79 |
| 2026-08-26 | RIOUX PATRICE | Acting Chief Medical Officer | Option exercise | 1,380 | $0.01 |
| 2026-08-26 | RIOUX PATRICE | Acting Chief Medical Officer | Open market sale | 1 | $111.26 |
| 2026-08-26 | Tsuchimoto Kim R | Director | Open market sale | 485 | $108.83 |
| 2026-08-26 | Tsuchimoto Kim R | Director | Open market sale | 615 | $109.56 |
| 2026-08-26 | Tsuchimoto Kim R | Director | Open market sale | 700 | $110.65 |
| 2026-08-26 | Tsuchimoto Kim R | Director | Open market sale | 1,098 | $111.84 |
| 2026-08-26 | Tsuchimoto Kim R | Director | Open market sale | 602 | $112.93 |
| 2026-08-26 | Tsuchimoto Kim R | Director | Open market sale | 590 | $113.84 |
| 2026-08-25 | Anderson Raymond | Director | Open market sale | 694 | $110.04 |
| 2026-08-25 | Anderson Raymond | Director | Open market sale | 646 | $110.07 |
| 2026-08-25 | Anderson Raymond | Director | Open market sale | 1,802 | $113.05 |
| 2026-06-30 | Vu Quan Anh | Chief Financial Officer | Option exercise | 1,228 | — |
| 2026-06-30 | Vu Quan Anh | Chief Financial Officer | Tax withholding | 507 | $92.59 |
| 2026-06-30 | Robinson Chandler | Chief Executive Officer | Option exercise | 12,873 | — |
| 2026-06-30 | Robinson Chandler | Chief Executive Officer | Tax withholding | 4,084 | $92.59 |
| 2026-06-30 | Cittadine Andrew | Chief Operating Officer | Option exercise | 5,254 | — |
| 2026-06-30 | Cittadine Andrew | Chief Operating Officer | Tax withholding | 2,309 | $92.59 |
| 2026-03-31 | Robinson Chandler | Chief Executive Officer | Option exercise | 6,732 | — |
| 2026-03-31 | Robinson Chandler | Chief Executive Officer | Tax withholding | 1,972 | $54.79 |
| 2026-03-31 | Cittadine Andrew | Chief Operating Officer | Option exercise | 3,514 | — |
| 2026-03-31 | Cittadine Andrew | Chief Operating Officer | Tax withholding | 1,571 | $54.79 |
| 2025-12-31 | Robinson Chandler | Chief Executive Officer | Option exercise | 8,724 | — |
| 2025-12-31 | Robinson Chandler | Chief Executive Officer | Tax withholding | 2,558 | $65.30 |
| 2025-12-31 | Cittadine Andrew | Chief Operating Officer | Option exercise | 4,326 | — |
| 2025-12-31 | Cittadine Andrew | Chief Operating Officer | Tax withholding | 1,889 | $65.30 |
| 2025-12-26 | Vu Quan Anh | Chief Financial Officer | Open market purchase | 1,500 | $69.95 |
| 2025-12-18 | KLAUSNER ARTHUR J | Director | Open market sale | 4,660 | $67.06 |
| 2025-12-18 | KLAUSNER ARTHUR J | Director | Open market sale | 461 | $68.09 |
| 2025-12-16 | Hendricks Diane | 10% owner | Other acquisition/disposition | 43,499 | $0.00 |
| 2025-12-16 | KLAUSNER ARTHUR J | Director | Other acquisition/disposition | 7,710 | $0.00 |
| 2025-01-28 | Robinson Chandler | Chief Executive Officer | Other acquisition/disposition | 62,815 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:32 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 4 | 2026-10-20 | View on SEC.gov → |
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-28 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-22 | 8-K | 2026-07-22 | View on SEC.gov → |
Recent news
Headlines about MNPR (Monopar Therapeutics Inc.). Links open the publisher — we don’t host full articles.
-
MNPR falls as seller pressure persists
Traders Union · 2026-10-21 -
An administrative error leads to 597 CEO shares withheld for tax at Monopar Therapeutics (MNPR).
Stock Titan · 2026-10-20 -
Monopar Therapeutics stock falls 5.60 percent below its gettex close
AD HOC NEWS · 2026-10-20 -
Monopar Therapeutics shares technical analysis: Upward price move faces $76.38 resistance
Traders Union · 2026-10-20 -
Monopar Therapeutics shares technical analysis: Upward price move faces $72.45 resistance
Traders Union · 2026-10-19 -
Monopar Therapeutics stock fell 3.52 percent on Nasdaq - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
Monopar Therapeutics shares technical analysis: Bearish signals persist with eyes on $65.17 support
Traders Union · 2026-10-16 -
This Monopar Therapeutics Insider Reduced Their Stake By 37%
Simply Wall Street · 2026-10-16
No headlines in this category right now — try “All”.